BioSpace News Archive

Hoth Therapeutics announced that it has entered into a Sponsored Research Agreement (“SRA”) with the George Washington University (“GW”) relating to the development of an in vitro diagnostic device that has the potential for testing by patients anywhere to allow public health professionals to immediately detect SARS-CoV-2 via a mobile device as an aid in the diagnosis of the COVID-19 infection.

Cabozantinib in combination with atezolizumab demonstrated promising preliminary efficacy and a favorable safety profile in cohorts of patients with clear cell and non-clear cell renal cell carcinoma – – Data presented during the European Society for Medical Oncology Virtual Congress 2020 – ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (NASDAQ: EXEL) today announced positive phase 1b clinical trial results for the combination o

Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 - Data Featured in Late-Breaking Proffered Paper Oral Presentation - - Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA - BOTHELL, Wash. & COPENHAGEN, Denmark--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) an

BioSig Technologies, Inc.’s subsidiary, ViralClear Pharmaceuticals, Inc., announced that it will host a call and webcast to discuss its Phase 2 clinical trial.

Sept. 21, 2020 15:15 UTC Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV) Results published in Nature Biomedical Engineering demonstrate potential of Qihan’s genome editing platform to cr

Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administration (NMPA) of its next-generation fully human anti-CTLA-4 antibody (HBM4003).

The annual open enrollment season is nearly underway, and U.S. employees will be making benefits decisions during an unprecedented and challenging time.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the launch of AVISE® Vasculitis AAV, a new testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of ANCA-associated vasculitis (AAV).

XBiotech Inc. (NASDAQ: XBIT) announced today it is developing a new breakthrough candidate therapy it calls FLUVID™ for treating illness caused by combined infections with influenza and COVID-19. With the global spread of the novel COVID-19 virus, there will be added risk during flu seasons that people may be infected by both influenza and COVID-19 viruses. Co-infections with the two viruses, or superinfections, may increase severity of disease

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.